Literature DB >> 15758476

The effects of growth hormone on cortical and cancellous bone.

T T Andreassen1, H Oxlund.   

Abstract

Growth hormone (GH) has profound effects on linear bone growth, bone metabolism and bone mass. The GH receptor is found on the cell surface of osteoblasts and osteoclasts, but not on mature osteocytes. In vitro, GH stimulates proliferation, differentiation and extracellular matrix production in osteoblast-like cell lines. GH also stimulates recruitment and bone resorption activity in osteoclast-like cells. GH promotes autocrine/paracrine insulin-like growth factor 1 (IGF-I) production and endocrine (liver-derived) IGF-I production. Some of the GH-induced effects on bone cells can be blocked by IGF-I antibodies, while others cannot. In animal experiments, GH administration increases bone formation and resorption, and enhances cortical bone mass and mechanical strength. When GH induces linear growth, increased cancellous bone volume is seen, but an unaffected cancellous bone volume is found in the absence of linear growth. Patients with acromegaly have increased bone formation and resorption markers. Bone mass results are conflicting because many acromegalics have hypogonadism, but in acromegalics without hypogonadism, increased bone mineral density (BMD) is seen in predominantly cortical bone, and normal BMD in predominantly cancellous bone. Adult patients with growth hormone deficiency have decreased bone mineral content and BMD. GH therapy rapidly increases bone formation and resorption markers. During the first 6-12 months of therapy, declined or unchanged BMD is found in the femoral neck and lumbar spine. All GH trials with a duration of two years or more show enhanced femoral neck and lumbar spine BMD. In osteoporotic patients, GH treatment quickly increases markers for bone formation and resorption. During the first year of treatment, unchanged or decreased BMD values are found, whereas longer treatment periods report enhanced or unchanged BMD values. However, existing trials comprising relatively few patients and limited treatment periods do not allow final conclusions to be drawn regarding the effects of GH on osteoporosis during long-term treatment.

Entities:  

Year:  2001        PMID: 15758476

Source DB:  PubMed          Journal:  J Musculoskelet Neuronal Interact        ISSN: 1108-7161            Impact factor:   2.041


  8 in total

Review 1.  Extrapituitary growth hormone.

Authors:  S Harvey
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

2.  Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3.

Authors:  Paola Nicoletti; Vassiliki M Cartsos; Penelope K Palaska; Yufeng Shen; Aris Floratos; Athanasios I Zavras
Journal:  Oncologist       Date:  2012-01-20

Review 3.  Diagnosis and treatment of growth hormone deficiency in adults.

Authors:  Atil Y Kargi; George R Merriam
Journal:  Nat Rev Endocrinol       Date:  2013-04-30       Impact factor: 43.330

4.  Effects of growth hormone on bone modeling and remodeling in hypophysectomized young female rats: a bone histomorphometric study.

Authors:  Lysette Iglesias; James K Yeh; Mariano Castro-Magana; John F Aloia
Journal:  J Bone Miner Metab       Date:  2010-07-23       Impact factor: 2.626

5.  Prevalence of osteoporosis and vertebral fractures in acromegalic patients.

Authors:  Giuseppina Padova; Graziella Borzì; Laura Incorvaia; Guido Siciliano; Valentina Migliorino; Mario Vetri; Patrizia Tita
Journal:  Clin Cases Miner Bone Metab       Date:  2011-09

Review 6.  Growth hormone deficiency in the transition period: body composition and gonad function.

Authors:  G Balercia; L Giovannini; F Paggi; M Spaziani; N Tahani; M Boscaro; A Lenzi; A Radicioni
Journal:  J Endocrinol Invest       Date:  2011-06-21       Impact factor: 4.256

7.  The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypes.

Authors:  Audrey Griveau; Clotilde Wiel; Dorian V Ziegler; Martin O Bergo; David Bernard
Journal:  Aging Cell       Date:  2020-03-20       Impact factor: 9.304

8.  The intriguing giant deer from the Bate cave (Crete): could paleohistological evidence question its taxonomy and nomenclature?

Authors:  Maria Rita Palombo; Marco Zedda
Journal:  Integr Zool       Date:  2021-04-06       Impact factor: 2.083

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.